Can You Gain Weight While on Wegovy?

Step 1: Recognise which kind of weight change you're actually seeing

Not every upward tick on the scales means Wegovy has stopped working. Natural day-to-day fluctuation from water retention, a heavy meal the night before, or hormonal changes across a menstrual cycle can add 1–3 kg that looks alarming but reflects nothing about fat tissue. A genuine, sustained gain over several consecutive weeks is a different matter.

The most common legitimate explanation during active treatment is inadequate dose. The titration schedule starts low on purpose: the starting dose is there to let your body adjust, not to produce the full therapeutic effect. Some people find their appetite suppression is modest until they reach a higher maintenance dose. If you are still in the early weeks of treatment and the scales haven't moved (or have nudged upward) that pattern may resolve as the dose increases, which is why how Wegovy works across the full dose schedule is worth understanding before drawing conclusions.

A third cause is behavioural compensation. A proportion of people unconsciously eat larger portions of calorie-dense foods once nausea from the early weeks settles, effectively replacing the calorie reduction the medicine was producing. Awareness alone often corrects this.

Step 2: Check for the factors that genuinely counteract semaglutide

Wegovy acts on GLP-1 receptors to reduce hunger signals and slow gastric emptying, as the NHS semaglutide medicines page explains. What it cannot do is neutralise a sustained calorie surplus. Several specific factors are known to push the scales upward even during active treatment.

Corticosteroids, certain antidepressants, antipsychotics and some antihypertensives are well-documented contributors to weight gain; if you have been started on any of these since beginning Wegovy, that may explain a change. Alcohol is high in calories and disinhibits eating, its effect compounds quickly. Reduced physical activity, whether from injury, low mood or a change in routine, removes a significant energy-expenditure component. Sleep disruption raises ghrelin, the hunger hormone, and can partially override appetite suppression.

There is also a smaller group of people for whom semaglutide at 2.4 mg produces limited response. Whether Wegovy can directly cause weight gain rather than simply fail to prevent it is a separate question, the short answer is that the medicine itself does not promote fat storage, but the scenario that triggers it may.

If you are tracking your doses carefully and have ruled out the above, a clinical conversation is the right next step rather than adjusting anything yourself.

Step 3: Understand what happens when treatment is paused or stopped

This is where weight gain on Wegovy is most consistently documented. The STEP 1 trial, published in the New England Journal of Medicine, found that participants who stopped semaglutide after 68 weeks regained roughly two-thirds of the weight lost within a year. The mechanism is straightforward: the appetite suppression stops when the medicine leaves the body, hunger returns to its pre-treatment level, and intake rises unless lifestyle changes have been firmly embedded. This is not a failure of willpower; it reflects how appetite regulation works biologically.

The practical implication is that pausing doses (even for a week or two) can produce a noticeable bounce. If you keep your pen in the fridge door alongside the milk, a visual cue to inject on the same day each week helps break the forgetting pattern that leads to unplanned gaps. For those who have paused for medical reasons, a prescriber will advise whether restarting at the previous dose or stepping back is appropriate; the Patient Information Leaflet and your prescribing team are the right guides here, not general estimates. It is also worth understanding why people gain weight on Wegovy after stopping or pausing, since the biological picture is more nuanced than simply resuming old habits.

Questions about gaining weight while on Wegovy after a gap are among the more common queries our clinical team receives.

Step 4: Know when to escalate to your prescribing team

A plateau of several weeks during titration is normal and does not require action beyond continuing the schedule. A sustained gain of more than 2–3 kg over four to six weeks, with no obvious dietary or lifestyle explanation, deserves clinical review. So does any gain accompanied by new symptoms (swelling, breathlessness, or abdominal discomfort) which may point to something unrelated to the medicine.

At nume, a qualified prescriber reviews every repeat order before it is dispensed. That review is an opportunity to flag a change in weight trajectory, a new medicine, or a concern about how treatment is going. You are not limited to the initial consultation. Our aftercare team is available seven days a week for exactly this kind of question.

For anyone weighing up options or wondering whether semaglutide is still the right choice for their situation, the wider context around weight-loss treatment options may help frame the decision. Concerns specifically about cost and value are covered on the Wegovy cost page. And for a broader look at the semaglutide evidence, the semaglutide overview covers the clinical picture in full.

If you have been on treatment for some time and are questioning whether it is still working, starting a fresh consultation is a reasonable step. There is no obligation, and a prescriber can give you a clearer answer than a general article can.